Eyenovia (NASDAQ:EYEN) Shares Scheduled to Reverse Split on Monday, February 3rd

Shares of Eyenovia, Inc. (NASDAQ:EYEN) are going to reverse split before the market opens on Monday, February 3rd. The 1-80 reverse split was announced on Tuesday, January 28th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 31st.

Eyenovia Price Performance

NASDAQ:EYEN opened at $0.04 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The company has a 50 day moving average price of $0.09 and a 200-day moving average price of $0.46. Eyenovia has a 1-year low of $0.04 and a 1-year high of $2.57. The firm has a market cap of $4.15 million, a price-to-earnings ratio of -0.05 and a beta of 1.31.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the business earned ($0.18) earnings per share. Equities research analysts forecast that Eyenovia will post -0.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EYEN. William Blair reiterated a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th. Finally, HC Wainwright lowered shares of Eyenovia from a “buy” rating to a “neutral” rating and dropped their target price for the company from $12.00 to $2.00 in a research report on Monday, November 18th.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eyenovia in the 2nd quarter valued at $26,000. Financial Management Network Inc. purchased a new stake in shares of Eyenovia during the third quarter worth $39,000. Nations Financial Group Inc. IA ADV raised its position in shares of Eyenovia by 78.6% in the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after buying an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares in the last quarter. Hedge funds and other institutional investors own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.